Literature DB >> 17097013

Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.

Yi Dai1, Zhi-feng Qiu, Tai-sheng Li, Yang Han, Ling-yan Zuo, Jing Xie, Xiao-jun Ma, Zheng-yin Liu, Ai-xia Wang.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) produces profound suppression of HIV replication, substantial increase in CD4(+) T cells, and partial reconstitution of the immune system. However, the numbers of subjects were small in previous Chinese studies. This study evaluated the efficacy and side effects of HAART in Chinese advanced AIDS patients.
METHODS: One hundred and three antiretroviral drug naive AIDS patients were enrolled in this study and were divided into two groups by their baseline CD4(+) count: < 100 cells/microl or > or = 100 cells/microl. Clinical, virological and immunological outcomes were monitored at baseline and at 1, 3, 6, 9 and 12 months during the course of treatment with HAART.
RESULTS: One patient died and another was lost from the follow-up. For the remaining 101 HIV/AIDS patients at the 12th month during the HAART, the plasma viral load (VL) was reduced to (3.2 +/- 0.7) lg copies/ml, the CD4(+) count increased to (168 +/- 51) cells/microl [among which the naive phenotype (CD45RA(+)CD62L(+)) increased to (49 +/- 27) cells/microl and the memory phenotype (CD45RA(-)) increased to (119 +/- 55) cells/microl], and the percentage of CD4(+)CD28(+) cells increased. At the same time, there was a significant reduction of CD8(+) T cell activation. In the 69 patients with the baseline CD4(+) count < 100 cells/microl, 37 had a VL < 50 copies/ml; while in the 34 patients with the baseline CD4(+) count > or = 100 cells/microl, 25 had a VL < 50 copies/ml, the difference between the two groups was statistically significant. The CD4(+) T cell count showed a two-phase increase during HAART and a significant positive correlation was shown between the change of CD4(+) count and plasma VL. Over 12 months of HAART, 10 patients had gastrointestinal side effects, 13 peripheral neuritis, 7 hepatic lesions, 8 hematological side effects, 8 skin rashes, 10 lipodystrophy and 1 renal calculus.
CONCLUSIONS: Immune reconstitution as well as the significantly improved clinical outcomes is observed in Chinese advanced AIDS patients after HAART. Side effects are common during HAART and require clinical attention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097013

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  5 in total

1.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

2.  Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study.

Authors:  Hui Zheng; Lu Wang; Peng Huang; Jessie Norris; Qing Wang; Wei Guo; Zhihang Peng; Rongbin Yu; Ning Wang
Journal:  BMC Public Health       Date:  2014-08-11       Impact factor: 3.295

3.  Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.

Authors:  Fred Stephen Sarfo; Maame Anima Sarfo; Betty Norman; Richard Phillips; George Bedu-Addo; David Chadwick
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 4.  HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Authors:  Julia L Finkelstein; Pooja Gala; Rosemary Rochford; Marshall J Glesby; Saurabh Mehta
Journal:  J Int AIDS Soc       Date:  2015-01-15       Impact factor: 5.396

5.  Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.

Authors:  Denis Nash; Monica Katyal; Martin W G Brinkhof; Olivia Keiser; Margaret May; Rachael Hughes; Francois Dabis; Robin Wood; Eduardo Sprinz; Mauro Schechter; Matthias Egger
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.